REDWOOD CITY, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that it has entered into a new five-year $52 million loan arrangement with CIBC Innovation Banking. Proceeds from the new term loan were used to retire a $50 million debt facility with the Company’s existing lender.
REDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing...
REDWOOD CITY, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced positive five-year results from its 181 patient randomized WATER study comparing Aquablation therapy to TURP, the historical standard of care for treating BPH.
Procept BioRobotics (NASDAQ:PRCT) closed its IPO after the underwriters exercised their option in full to buy additional shares.
The surgical robotics company Procept BioRobotics (NASDAQ:PRCT) has gained more than 40% on its public debut following an upsized IPO that priced 6.6M shares of the common stock at $25.00 apiece.
With about 40 million men in the U.S. living with BPH, Procept Biorobotics has developed a treatment device that holds water.